GlassScriptPhysician profile
Kermit A Lloyd
NPI 1851325328
$257,191.23
in general payments reported to CMS, 2019-2025
27 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $44K · 2021: $25K · 2022: $25K · 2023: $31K · 2024: $54K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Travel and Lodging: $7,640 · Food and Beverage: $6,355 · Consulting Fee: $1,338 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,381.00 |
| Travel and Lodging | $7,639.82 |
| Food and Beverage | $6,355.14 |
| Consulting Fee | $1,338.00 |
| Education | $390.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $126,478.15 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $97,598.37 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $30,810.54 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $549.54 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $443.66 | 2019-2025 | |
| Genzyme Corporation | $258.62 | 2019-2023 | |
| Ceribell, INC. | $211.02 | 2025 | Pocket Eeg Device |
| Genentech, INC. | $192.88 | 2022-2025 | Ocrevus |
| Medtronic, INC. | $146.94 | 2022 | |
| Amgen INC. | $95.77 | 2021-2025 | Uplizna |
| Allergan, INC. | $92.46 | 2019-2021 | |
| Abbvie INC. | $74.80 | 2022-2025 | |
| Genentech USA, INC. | $63.01 | 2019-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Livanova USA, INC. | $31.44 | 2019-2020 | |
| Lundbeck LLC | $31.27 | 2025 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.66 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.27 | 2019 | |
| Vanda Pharmaceuticals INC. | $18.61 | 2025 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $13.45 | 2019 | |
| Lilly USA, LLC | $13.44 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kermit Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.